Women Healthcare Market Dynamics 2021-2031
The women healthcare market was valued at US$ 30.5 billion in 2021 and is likely to reach US$ 42.8 billion by 2031; it is expected to grow at a CAGR of 4.8% between 2022 and 2031.
Women's health directs to the branch of medicine that focuses on treating and diagnosing diseases and conditions affecting women's physical and emotional well-being. Women usually experience unique health care challenges and are more likely to be diagnosed with certain diseases than men. Chronic diseases and conditions such as heart disease, cancer, and diabetes are the leading causes of death among women. Other health concerns impacting women include maternal health issues, urinary tract infections, sexual health, and osteoporosis.
MARKET DYNAMICS
The small and big companies operating in the women healthcare market are adopting various strategies, including regional expansion and technological advancements, to increase their market share. Growing incidence of chronic health conditions among women, rising government initiatives to restrain population growth, and increasing demand for contraceptives to control unintended pregnancies are other factors propelling the market growth. Moreover, key players' growing focus on R&D for developing advanced products is a significant market driver. Long-term extreme adverse effects of oral contraceptive pills, such as stroke, decreased libido, blood clots, vaginal discharge, and augmented risk of breast cancer, may limit usage and lead to restrictions by regulatory agencies. Such factors may hinder the market growth during the forecast period.
MARKET SCOPE
The "Global Women Healthcare market Analysis to 2031" report aims to provide an overview of the women healthcare market with detailed market segmentation based on drug and application. The report provides key statistics based on the financial performances of the leading market players. It also offers key trends and opportunities in the market.
Strategic Insights
MARKET SEGMENTATION
The global women healthcare market is segmented based on drug and application. Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, and others. In terms of application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, and others.
The global women healthcare market is segmented into five major regions—North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and South & Central America. The report covers analysis and forecast of 18 countries globally, along with trends and opportunities prevailing in all the above-mentioned regions.
North America dominates the women healthcare market. The market in North America is majorly driven by the growing prevalence of polycystic ovary syndrome (PCOS) and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and rising healthcare spending in the US and Canada. According to the World Health Organization (WHO), in 2021, globally, around 190 million women of reproductive age were affected by endometriosis. Also, the increased awareness and familiarity regarding contraceptives among women and the easy access to modern contraception compared to developing countries are fueling the market growth in this region.
The below figure shows the revenue growth trend in the North America women healthcare market:
Source: The Insight Partners Analysis
The report analyzes factors such as drivers, restraints, opportunities, and future trends, which impact the growth of the women healthcare market. The report also provides a PEST analysis highlighting the factors affecting the women healthcare market in these regions.
IMPACT OF COVID-19 PANDEMIC
According to the World Health Organization (WHO), as of August 2022, there were 596,873,121 confirmed cases of COVID-19 and 6,459,684 deaths. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia. Due to economic uncertainty caused by COVID-19, limited transit options and travel limitations created impediments to international trade and transportation, affecting the supply chain for women's health diagnostics and temporarily lowering demand. The COVID-19 pandemic disrupted the supply chain of contraceptives, thus affecting sexual and reproductive health services. Also, due to COVID-19, several health services was forced to suspended or postponed. Thus, during the initial days, the COVID-19 pandemic had a negative impact on the women health care market.
Mrinal Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any. 
Have a question?
Speak to Analyst
The global women healthcare market is segmented into five major regions—North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and South & Central America. The report covers analysis and forecast of 18 countries globally, along with trends and opportunities prevailing in all the above-mentioned regions.
North America dominates the women healthcare market. The market in North America is majorly driven by the growing prevalence of polycystic ovary syndrome (PCOS) and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and rising healthcare spending in the US and Canada. According to the World Health Organization (WHO), in 2021, globally, around 190 million women of reproductive age were affected by endometriosis. Also, the increased awareness and familiarity regarding contraceptives among women and the easy access to modern contraception compared to developing countries are fueling the market growth in this region.
The below figure shows the revenue growth trend in the North America women healthcare market:
Source: The Insight Partners Analysis
The report analyzes factors such as drivers, restraints, opportunities, and future trends, which impact the growth of the women healthcare market. The report also provides a PEST analysis highlighting the factors affecting the women healthcare market in these regions.
IMPACT OF COVID-19 PANDEMIC
According to the World Health Organization (WHO), as of August 2022, there were 596,873,121 confirmed cases of COVID-19 and 6,459,684 deaths. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia. Due to economic uncertainty caused by COVID-19, limited transit options and travel limitations created impediments to international trade and transportation, affecting the supply chain for women's health diagnostics and temporarily lowering demand. The COVID-19 pandemic disrupted the supply chain of contraceptives, thus affecting sexual and reproductive health services. Also, due to COVID-19, several health services was forced to suspended or postponed. Thus, during the initial days, the COVID-19 pandemic had a negative impact on the women health care market.
MARKET PLAYERS
The report covers key developments in the women healthcare market. Various companies are focusing on organic growth strategies such as product launches, product approvals, and patents and events. In addition, acquisitions, partnerships, and collaborations are among the inorganic growth strategies witnessed in the market. These activities have paved the way for the expansion of business and the customer base of market players. The players operating in the women healthcare market are anticipated to experience lucrative growth opportunities in the future owing to the rising demand for women health care products.
The report also includes the profiles of key women healthcare market companies along with their SWOT analysis and market strategies. In addition, it focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last three years, and key development in the past five years.
Below mentioned is the list of a few companies engaged in the women healthcare market.
- Bayer AG
- Allergan plc
- Merck & Co.
- Pfizer Inc.
- Amgen Inc.
- Agile Therapeutics Inc.
- Ferring Pharmaceuticals
- Mylan N.V.
- Lupin Limited
- Blairex Laboratories
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug, Application, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Women Health Care Market - By Drug
1.3.2 Women Health Care Market - By Application
1.3.3 Women Health Care Market - By Distribution Channel
1.3.4 Women Health Care Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. WOMEN HEALTH CARE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. WOMEN HEALTH CARE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. WOMEN HEALTH CARE MARKET - GLOBAL MARKET ANALYSIS
6.1. WOMEN HEALTH CARE - GLOBAL MARKET OVERVIEW
6.2. WOMEN HEALTH CARE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. WOMEN HEALTH CARE MARKET - REVENUE AND FORECASTS TO 2028 - DRUG
7.1. OVERVIEW
7.2. DRUG MARKET FORECASTS AND ANALYSIS
7.3. XGEVA
7.3.1. Overview
7.3.2. XGEVA Market Forecast and Analysis
7.4. MIRENA
7.4.1. Overview
7.4.2. Mirena Market Forecast and Analysis
7.5. EVISTA
7.5.1. Overview
7.5.2. EVISTA Market Forecast and Analysis
7.6. PROLIA
7.6.1. Overview
7.6.2. Prolia Market Forecast and Analysis
7.7. ZOMETA
7.7.1. Overview
7.7.2. Zometa Market Forecast and Analysis
7.8. RECLAST/ACLASTA
7.8.1. Overview
7.8.2. Reclast/Aclasta Market Forecast and Analysis
7.9. MINASTRIN 24 FE
7.9.1. Overview
7.9.2. Minastrin 24 Fe Market Forecast and Analysis
7.10. NUVARING
7.10.1. Overview
7.10.2. NuvaRing Market Forecast and Analysis
7.11. PREMARIN
7.11.1. Overview
7.11.2. Premarin Market Forecast and Analysis
7.12. FORTEO
7.12.1. Overview
7.12.2. FORTEO Market Forecast and Analysis
7.13. ACTONEL
7.13.1. Overview
7.13.2. ACTONEL Market Forecast and Analysis
7.14. OTHERS
7.14.1. Overview
7.14.2. Others Market Forecast and Analysis
8. WOMEN HEALTH CARE MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. POSTMENOPAUSAL OSTEOPOROSIS
8.3.1. Overview
8.3.2. Postmenopausal Osteoporosis Market Forecast and Analysis
8.4. MENOPAUSE
8.4.1. Overview
8.4.2. Menopause Market Forecast and Analysis
8.5. ENDOMETRIOSIS
8.5.1. Overview
8.5.2. Endometriosis Market Forecast and Analysis
8.6. HORMONAL INFERTILITY
8.6.1. Overview
8.6.2. Hormonal Infertility Market Forecast and Analysis
8.7. CONTRACEPTIVES
8.7.1. Overview
8.7.2. Contraceptives Market Forecast and Analysis
8.8. OTHER
8.8.1. Overview
8.8.2. Other Market Forecast and Analysis
9. WOMEN HEALTH CARE MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. DRUG STORES AND RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Drug Stores and Retail pharmacies Market Forecast and Analysis
9.5. ONLINE PROVIDERS
9.5.1. Overview
9.5.2. Online Providers Market Forecast and Analysis
10. WOMEN HEALTH CARE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Women Health Care Market Overview
10.1.2 North America Women Health Care Market Forecasts and Analysis
10.1.3 North America Women Health Care Market Forecasts and Analysis - By Drug
10.1.4 North America Women Health Care Market Forecasts and Analysis - By Application
10.1.5 North America Women Health Care Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Women Health Care Market Forecasts and Analysis - By Countries
10.1.6.1 United States Women Health Care Market
10.1.6.1.1 United States Women Health Care Market by Drug
10.1.6.1.2 United States Women Health Care Market by Application
10.1.6.1.3 United States Women Health Care Market by Distribution Channel
10.1.6.2 Canada Women Health Care Market
10.1.6.2.1 Canada Women Health Care Market by Drug
10.1.6.2.2 Canada Women Health Care Market by Application
10.1.6.2.3 Canada Women Health Care Market by Distribution Channel
10.1.6.3 Mexico Women Health Care Market
10.1.6.3.1 Mexico Women Health Care Market by Drug
10.1.6.3.2 Mexico Women Health Care Market by Application
10.1.6.3.3 Mexico Women Health Care Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Women Health Care Market Overview
10.2.2 Europe Women Health Care Market Forecasts and Analysis
10.2.3 Europe Women Health Care Market Forecasts and Analysis - By Drug
10.2.4 Europe Women Health Care Market Forecasts and Analysis - By Application
10.2.5 Europe Women Health Care Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Women Health Care Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Women Health Care Market
10.2.6.1.1 Germany Women Health Care Market by Drug
10.2.6.1.2 Germany Women Health Care Market by Application
10.2.6.1.3 Germany Women Health Care Market by Distribution Channel
10.2.6.2 France Women Health Care Market
10.2.6.2.1 France Women Health Care Market by Drug
10.2.6.2.2 France Women Health Care Market by Application
10.2.6.2.3 France Women Health Care Market by Distribution Channel
10.2.6.3 Italy Women Health Care Market
10.2.6.3.1 Italy Women Health Care Market by Drug
10.2.6.3.2 Italy Women Health Care Market by Application
10.2.6.3.3 Italy Women Health Care Market by Distribution Channel
10.2.6.4 Spain Women Health Care Market
10.2.6.4.1 Spain Women Health Care Market by Drug
10.2.6.4.2 Spain Women Health Care Market by Application
10.2.6.4.3 Spain Women Health Care Market by Distribution Channel
10.2.6.5 United Kingdom Women Health Care Market
10.2.6.5.1 United Kingdom Women Health Care Market by Drug
10.2.6.5.2 United Kingdom Women Health Care Market by Application
10.2.6.5.3 United Kingdom Women Health Care Market by Distribution Channel
10.2.6.6 Rest of Europe Women Health Care Market
10.2.6.6.1 Rest of Europe Women Health Care Market by Drug
10.2.6.6.2 Rest of Europe Women Health Care Market by Application
10.2.6.6.3 Rest of Europe Women Health Care Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Women Health Care Market Overview
10.3.2 Asia-Pacific Women Health Care Market Forecasts and Analysis
10.3.3 Asia-Pacific Women Health Care Market Forecasts and Analysis - By Drug
10.3.4 Asia-Pacific Women Health Care Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Women Health Care Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Women Health Care Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Women Health Care Market
10.3.6.1.1 Australia Women Health Care Market by Drug
10.3.6.1.2 Australia Women Health Care Market by Application
10.3.6.1.3 Australia Women Health Care Market by Distribution Channel
10.3.6.2 China Women Health Care Market
10.3.6.2.1 China Women Health Care Market by Drug
10.3.6.2.2 China Women Health Care Market by Application
10.3.6.2.3 China Women Health Care Market by Distribution Channel
10.3.6.3 India Women Health Care Market
10.3.6.3.1 India Women Health Care Market by Drug
10.3.6.3.2 India Women Health Care Market by Application
10.3.6.3.3 India Women Health Care Market by Distribution Channel
10.3.6.4 Japan Women Health Care Market
10.3.6.4.1 Japan Women Health Care Market by Drug
10.3.6.4.2 Japan Women Health Care Market by Application
10.3.6.4.3 Japan Women Health Care Market by Distribution Channel
10.3.6.5 South Korea Women Health Care Market
10.3.6.5.1 South Korea Women Health Care Market by Drug
10.3.6.5.2 South Korea Women Health Care Market by Application
10.3.6.5.3 South Korea Women Health Care Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Women Health Care Market
10.3.6.6.1 Rest of Asia-Pacific Women Health Care Market by Drug
10.3.6.6.2 Rest of Asia-Pacific Women Health Care Market by Application
10.3.6.6.3 Rest of Asia-Pacific Women Health Care Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Women Health Care Market Overview
10.4.2 Middle East and Africa Women Health Care Market Forecasts and Analysis
10.4.3 Middle East and Africa Women Health Care Market Forecasts and Analysis - By Drug
10.4.4 Middle East and Africa Women Health Care Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Women Health Care Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Women Health Care Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Women Health Care Market
10.4.6.1.1 South Africa Women Health Care Market by Drug
10.4.6.1.2 South Africa Women Health Care Market by Application
10.4.6.1.3 South Africa Women Health Care Market by Distribution Channel
10.4.6.2 Saudi Arabia Women Health Care Market
10.4.6.2.1 Saudi Arabia Women Health Care Market by Drug
10.4.6.2.2 Saudi Arabia Women Health Care Market by Application
10.4.6.2.3 Saudi Arabia Women Health Care Market by Distribution Channel
10.4.6.3 U.A.E Women Health Care Market
10.4.6.3.1 U.A.E Women Health Care Market by Drug
10.4.6.3.2 U.A.E Women Health Care Market by Application
10.4.6.3.3 U.A.E Women Health Care Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Women Health Care Market
10.4.6.4.1 Rest of Middle East and Africa Women Health Care Market by Drug
10.4.6.4.2 Rest of Middle East and Africa Women Health Care Market by Application
10.4.6.4.3 Rest of Middle East and Africa Women Health Care Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Women Health Care Market Overview
10.5.2 South and Central America Women Health Care Market Forecasts and Analysis
10.5.3 South and Central America Women Health Care Market Forecasts and Analysis - By Drug
10.5.4 South and Central America Women Health Care Market Forecasts and Analysis - By Application
10.5.5 South and Central America Women Health Care Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Women Health Care Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Women Health Care Market
10.5.6.1.1 Brazil Women Health Care Market by Drug
10.5.6.1.2 Brazil Women Health Care Market by Application
10.5.6.1.3 Brazil Women Health Care Market by Distribution Channel
10.5.6.2 Argentina Women Health Care Market
10.5.6.2.1 Argentina Women Health Care Market by Drug
10.5.6.2.2 Argentina Women Health Care Market by Application
10.5.6.2.3 Argentina Women Health Care Market by Distribution Channel
10.5.6.3 Rest of South and Central America Women Health Care Market
10.5.6.3.1 Rest of South and Central America Women Health Care Market by Drug
10.5.6.3.2 Rest of South and Central America Women Health Care Market by Application
10.5.6.3.3 Rest of South and Central America Women Health Care Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL WOMEN HEALTH CARE MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. WOMEN HEALTH CARE MARKET, KEY COMPANY PROFILES
13.1. BAYER AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ALLERGAN
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. MERCK AND CO.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. PFIZER INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. AMGEN
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. AGILE THERAPEUTICS INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. FERRING PHARMACEUTICALS
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. MYLAN N.V.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. LUPIN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BLAIREX LABORATORIES
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Bayer AG
2. Allergan
3. Merck & Co.
4. Pfizer Inc.
5. Amgen
6. Agile Therapeutics Inc.
7. Ferring Pharmaceuticals
8. Mylan N.V.
9. Lupin
10. Blairex Laboratories
11. Apothecus Pharmaceutical
12. Eli Lilly and Company
13. Novartis AG
14. Johnson & Johnson
15. AstraZeneca
16. Bristol-Myers Squib
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For